Because each drug targets a different part of the cancer [179, 187], it is possible that cGAS-STING agonists can maximize the downstream anti-tumor response while reducing the required dose of the conventional chemotherapy drug(s), and the potential side effects. The gene discussed is STING1; the disease is cancer.